<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Gallant, Joel E.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">What's New in Antiretroviral Therapy</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">19-20</style></pages><abstract><style  face="normal" font="default" size="100%">Current guidelines recommend non-nucleoside reverse transcriptase inhibitor (NNRTI)-based, boosted protease inhibitor (PI)-based, and integrase strand transfer inhibitor (INSTI)-based regimens for the treatment of HIV [http://aidsinfo.nih.gov/Guidelines/HTML/1/adult-and-adolescent-treatment-guidelines/0; Thompson MA et al. JAMA 2012]. This article discusss recent data from clinical trials comparing initial antiretroviral regimens and factors to be considered when starting antiretroviral therapy.</style></abstract><number><style face="normal" font="default" size="100%">14</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>